According to Teva Pharmaceutical, a decentralized procedure for its Braltus tiotropium bromide DPI for the treatment of COPD has reached “a positive conclusion.” The tiotropium formulation is delivered using the new Zonda inhaler, the company said. No additional information was released other than the company’s statement that “National Marketing Authorizations and launches will take place in selected markets over the coming months as assessed by national Teva companies.”
Teva’s Head of Respiratory, Europe, Luca Frangoni said, “We are all excited at the news of the positive conclusion for the DCP in Europe, and our local companies are looking forward to the opportunity of bringing Braltus to their local COPD communities. It is an important goal of our growing respiratory franchise to bring new treatment options to healthcare professionals who support people living with long-term chronic conditions including COPD. We want to give patients an effective role in their own treatment while at the same time aiming to reduce costs for healthcare systems.”
Read the Teva press release.
